Company intelligence / Profile preview
Resproly
- Ownership
- Private
- Employees
- ~200
- Development stage
- Preclinical
Overview
Resproly has developed a pipeline of inhaled therapies for respiratory and CNS diseases. Its lead proprietary candidate RSN0402 is in Phase 1 clinical trials for idiopathic pulmonary fibrosis. The company also develops generic versions of established inhaled drugs and has experience with complex generics approved in major markets.
- Therapeutic areas
- PulmonologyCardiovascularNeurology
- Modalities
- Small moleculesInhaled drug formulations (MDI, DPI, nebulizers, nasal sprays)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Resproly.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Resproly.